Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02701153

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
51 (estimated)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies the side effects of hypofractionated radiation therapy in treating patients with soft tissue sarcomas prior to surgery. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Detailed description

PRIMARY OBJCETIVES: I. Grade \>= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema) at 2 years. SECONDARY OBJECTIVES: I. Evaluate local control, regional control, distant metastasis, progression free survival, and overall survival. II. Evaluate the functional outcomes as assessed using the musculoskeletal tumor rating scale (MSTS) and the Toronto Extremity Salvage Score (TESS). III. Collect germ-line deoxyribonucleic acid (DNA) and nucleic acids from cancer patients to further investigate the association and identify new germ-line mutations that impact cancer predisposition. IV. Investigate the role of germ-line mutations in predicting cancer outcome and response to therapy. OUTLINE: Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery. After completion of study treatment, patients are followed up at 3 months and then every 6 months for 5 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREConventional SurgeryUndergo surgery
RADIATIONHypofractionated Radiation TherapyUndergo hypofractionated radiation therapy
OTHERLaboratory Biomarker AnalysisCorrelative studies
OTHERQuestionnaire AdministrationAncillary studies

Timeline

Start date
2016-02-03
Primary completion
2027-02-03
Completion
2028-02-03
First posted
2016-03-08
Last updated
2026-03-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02701153. Inclusion in this directory is not an endorsement.